Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by ...

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...

The data, which will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, builds upon earlier results presented at ASCO. The study showed a disease control rate of 93.8% at the ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...